Correlation Between Inhibrx and Elevation Oncology

Can any of the company-specific risk be diversified away by investing in both Inhibrx and Elevation Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and Elevation Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inhibrx and Elevation Oncology, you can compare the effects of market volatilities on Inhibrx and Elevation Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of Elevation Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and Elevation Oncology.

Diversification Opportunities for Inhibrx and Elevation Oncology

-0.08

Correlation Coefficient

Inhibrx  Elevation Oncology

Good diversification

The 3 months correlation between Inhibrx and Elevation is -0.08. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and Elevation Oncology in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Elevation Oncology and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with Elevation Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Elevation Oncology has no effect on the direction of Inhibrx i.e., Inhibrx and Elevation Oncology go up and down completely randomly.

Pair Corralation between Inhibrx and Elevation Oncology

Given the investment horizon of 90 days Inhibrx is expected to generate 0.41 times more return on investment than Elevation Oncology. However, Inhibrx is 2.42 times less risky than Elevation Oncology. It trades about -0.02 of its potential returns per unit of risk. Elevation Oncology is currently generating about -0.11 per unit of risk. If you would invest  1,514  in Inhibrx on December 30, 2024 and sell it today you would lose (102.00) from holding Inhibrx or give up 6.74% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Inhibrx  vs.  Elevation Oncology

Inhibrx

Risk-Adjusted Performance

Very Weak

Over the last 90 days Inhibrx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Elevation Oncology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Elevation Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Inhibrx and Elevation Oncology

The main advantage of trading using opposite Inhibrx and Elevation Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, Elevation Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elevation Oncology will offset losses from the drop in Elevation Oncology's long position.

The idea behind Inhibrx and Elevation Oncology pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.